Tumor regression and pharmacodynamic (PD) biomarker validation in non-small cell lung cancer (NSCLC) patients treated with the ErbB/VEGFR inhibitor BMS-690514

Bahleda, Ratislav; Soria, Jean‐Charles; Harbison, C.; Park, J.; Felip, Enriqueta; Hanna, Nadine; A. Laurie, Scott; Armand, P.; A. Shepherd, Frances; S. Herbst, Roy

doi:10.1200/jco.2009.27.15_suppl.8098

Public

Tumor regression and pharmacodynamic (PD) biomarker validation in non-small cell lung cancer (NSCLC) patients treated with the ErbB/VEGFR inhibitor BMS-690514

Shared by NobleBlocks on May 20, 2009 • 12:00 AM UTC

Authors:

Ratislav Bahleda

Jean‐Charles Soria

C. Harbison

Abstract

8098 Background: BMS-690514 is an oral selective inhibitor of EGFR, HER2, and VEGFR1–3. Previous results from the phase I portion of this phase I/II study established 200 mg/day as safe and tolerable (ASCO 2008; abstr 2564). Methods: Erlotinib-naïve and erlotinib-resistant adult patients with advanc...

Subject

Erlotinib

Medicine

Rash

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!